Beta-blockers after myocardial infarction: Are they useful to all patients? And how long should be the beta-blocker therapy?

Submitted: May 27, 2018
Accepted: May 28, 2018
Published: June 7, 2018
Abstract Views: 3168
PDF: 582
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Some observational studies raised questions about the need for β-blockers in all patients after a first heart attack. Surprisingly, in some clinical settings, a limited mortality reduction was found in those who received β-blockade.Some studies suggest that patients without heart failure may not need post-MI β-blockers. The lack of data from randomized controlled clinical trials has led to clinical uncertainty and conflicting recommendations. Therefore, there are multiple information to revaluate the value of β-blocker therapy after a heart attack in absence of heart failure or left ventricular dysfunction and the time for new trials of an old group of drugs has arrived.



PlumX Metrics


Download data is not yet available.


How to Cite

Pedretti, Roberto F.E. 2018. “Beta-Blockers After Myocardial Infarction: Are They Useful to All Patients? And How Long Should Be the Beta-Blocker Therapy?”. Monaldi Archives for Chest Disease 88 (2).